Kathy is an internationally recognised healthcare and life sciences leader with deep and broad investment and licensing expertise, delivering a solid track record of value creating deals across pharmaceuticals, medtech, vaccines consumer and digital healthcare for some of the world’s largest companies.
For the past 20 years, Kathy has held senior executive leadership positions in biotechnology, pharmaceutical, medical device and consumer health sectors specialising in business development, licensing, acquisitions and venture investment, as well as having worked in healthcare and lifesciences executive search and management consulting with Korn Ferry. During her tenure at Johnson & Johnson and Sanofi, Kathy led external innovation investment, licensing and acquisition across ANZ, with more than $US1B of capital being deployed in Australia with industry, academia, VCs and government organisations.
A dedicated advocate of diversity, equity and inclusion, Kathy co-founded Medicines Australia’s Pharmaceutical Australia Inclusion Group (PAIG) – a special working group designed to foster diverse and inclusive corporate cultures and was awarded BioMelbourne Network’s Woman of the Year in 2018 for her leadership in supporting Australia’s high priority strategic growth sectors of biotech, medtech and pharmaceuticals.
In addition to serving Proto Axiom as Non-Executive Director, Kathy is also a Non-Executive Director for ASX listed biotechnology companies Avecho and Opthea as well as BioNSW, the peak body for Life Sciences companies and professionals in NSW and is an advisory board member for Flinders University Medical Device Research Institute. Kathy is a registered psychologist, holding tertiary degrees and qualifications in Applied Science, Psychology, Mediation and Law as well as being a Graduate of the Australian Institute of Company Directors.
.png)
